Read by QxMD icon Read


shared collection
4 papers 0 to 25 followers
Jose F Falantes, Guillermo Garcia-Manero
No abstract text is available yet for this article.
October 2015: Leukemia Research
Amer M Zeidan, Mikkael A Sekeres, Xiao-Feng Wang, Najla Al Ali, Guillermo Garcia-Manero, David P Steensma, Gail Roboz, John Barnard, Eric Padron, Amy Dezern, Jaroslaw P Maciejewski, Alan F List, Rami S Komrokji
Some patients classified as having lower-risk (LR)-disease by the International Prognostic Scoring System (IPSS) fare more poorly than predicted. We examined the prognostic utility of IPSS, the MD Anderson LR-Prognostic System (LR-PSS) and the revised IPSS (IPSS-R) in a large cohort of patients classified as having IPSS LR-MDS in the MDS Clinical Research Consortium database. Actual overall survival (OS) was assessed in patients with IPSS LR-MDS (i.e. low and intermediate-1) using Kaplan-Meier methods. Harrell's c index (HCI) and Akaike information criteria (AIC) were used to compare the models...
August 11, 2015: American Journal of Hematology
Romain Guièze, Gandhi Damaj, Bruno Pereira, Marie Robin, Patrice Chevallier, Mauricette Michallet, Stéphane Vigouroux, Yves Beguin, Didier Blaise, Jean El Cheikh, Damien Roos-Weil, Anne Thiebaut, Pierre-Simon Rohrlich, Anne Huynh, Jérôme Cornillon, Nathalie Contentin, Felipe Suarez, Bruno Lioure, Mohamad Mohty, Natacha Maillard, Laurence Clement, Sylvie François, Gaëlle Guillerm, Ibrahim Yakoub-Agha
To find out prognostic factors and to investigate different therapeutic approaches, we report on 147 consecutive patients who relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndrome (MDS). Sixty-two patients underwent immunotherapy (IT group, second allo-HSCT or donor lymphocyte infusion), 39 received cytoreductive treatment alone (CRT group) and 46 were managed with palliative/supportive cares (PSC group). Two-year rates of overall survival (OS) were 32%, 6%, and 2% in the IT, CRT, and PSC groups, respectively (P < ...
February 2016: Biology of Blood and Marrow Transplantation
Rafael Bejar, Allegra Lord, Kristen Stevenson, Michal Bar-Natan, Albert Pérez-Ladaga, Jacques Zaneveld, Hui Wang, Bennett Caughey, Petar Stojanov, Gad Getz, Guillermo Garcia-Manero, Hagop Kantarjian, Rui Chen, Richard M Stone, Donna Neuberg, David P Steensma, Benjamin L Ebert
Only a minority of myelodysplastic syndrome (MDS) patients respond to hypomethylating agents (HMAs), but strong predictors of response are unknown. We sequenced 40 recurrently mutated myeloid malignancy genes in tumor DNA from 213 MDS patients collected before treatment with azacitidine (AZA) or decitabine (DEC). Mutations were examined for association with response and overall survival. The overall response rate of 47% was not different between agents. Clonal TET2 mutations predicted response (odds ratio [OR] 1...
October 23, 2014: Blood
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"